You are here
Risk of Incremental Toxicities and Associated Costs of New Anticancer Drugs: A Meta-Analysis
Niraula S, Amir E, Vera-Badillo F, Seruga B, Ocana A, Tannock IF.
J Clin Oncol. 2014 Sep 29. pii: JCO.2014.55.8437.
Editors’ comments: Dr Ricardo Caponero
Newly approved anticancer drugs are associated with increased toxicity, except for agents with a specific molecular target on cancer cells. Management of toxicity leads to a small increase in overall cost of treatment. Frequency of toxicity and associated costs are likely higher in less-selected patients treated in general oncologic practice.